DNA vaccination for induction of suppressive T cell response
Patent 5939400 Issued on August 17, 1999. Estimated Expiration Date: February 26, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/44, Polynucleotide (e.g., RNA, DNA, etc.)424/93.21, Eukaryotic cell435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell800/9The nonhuman animal is a model for human disease
A pro-inflammatory T response is specifically prevented by the injection into a recipient of DNA encoding the variable region of a T cell receptor. In response to the vaccination, T cells expressing the variable region produce Th2 cytokines, including IL-4. A pro-inflammatory T cell response directed to an autoantigen is shown to be suppressed by DNA vaccination. The suppressive vaccination further reduced the inflammatory effect of T cells reactive against epitopes of the autoantigen not recognized by the variable region used for vaccination.
Other References
Waisman et al., Nature Medicine, vol. 2, pp. 899-905, Aug. 1996
Orkin et al., Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995
Coghlan, Focus, vol. 148, pp. 14-15, Nov. 25, 1995
Brown, "News Media, Researchers `Oversold` Gene Therapy, Advisory Panel Says", The Washington Post, Dec. 8, 1995
Marshall, Science, vol. 269, pp. 1050-1055, Aug. 25, 1995
Anderson, Human Gene Therapy, vol. 5, pp. 281-282, 1994
Challita & Kohn, Procedures of the National Academy of Sciences, U.S.A., vol. 91, pp. 2567-2571, Mar. 1994
Jaroff, Time, vol. 148, pp. 24-29, Sep. 1996
Vandenbark et al., Nature, vol. 341, pp. 541-544, 1989
Steinman, Cell, vol. 80, pp. 7-10, Jan. 13, 1995
Chou et al., Procedures of the National Academy of Sciences, U.S.A., vol. 84, pp. 1992-1996, 1987
Steinman, L., (1996), "A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry," Proc. Natl. Acad. Sci. USA, 93, 2253-56
Xu and Liew, "Protection Against Leishmaniasis by Injection of DNA Encoding a Major Surface Glycoprotein, gp63, of L. major," Immunology (1995), 84:173-176
Mor et al., "Complexity of the Cytokine and Antibody Response Elicited by Immunizing Mice with Plasmodium Yoelii Circumsporozoite Protein Plasmid DNA," J. of Immunology (1995), 2039-2046
Katz et al., "T Helper Cell Subsets in Insulin-Dependent Diabetes," Science (May 1995), 268:1185-1188
Rohane et al., "Islet-Infiltrating Lymphocytes from Prediabetic NOD Mice Rapidly Transfer Diabetes to NOD-scid/scid Mice," Diabetes (May 1995), 44:550-554
Weiner et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol. (1994), 12:809-837
Davis et al., "Direct Gene Transfer in Skeletal Muscle: Plasmid DNA-based Immunization Against the Hepatitis B Virus Surface Antigen," Vaccine (1994), 12:1503-1509
Davis et al., "DNA-Based Immunization Induces Continuous Secretion of Hepatitis B Surface Antigen and High Levels of Circulating Antibody," Human Molecular Genetics (1993), 2:1847-1851
Ulmer et al., Heterologous Protection Against Influenza by Injecting of DNA Encoding a Viral Protein, Science (Mar. 1993), 259:1745-1749
Martin et al., "Diversity in Fine Specificity and T Cell Receptor Usage of The Human CD4+ Cytotoxic T Cell Response Specific For the Immunodominant Myelin Basic Protein Peptide 87-106," J. of Immunology (Mar. 1992), 148:1359-1366
Tang et al., "Genetic Immunization is a Simple Method for Eliciting an Immune Response," Nature (Mar. 1992), 356:152-154
Martin et al., "A Myelin Basic Protein Peptide is Recognized by Cytotoxic T Cells in the Context of Four HLA-DR Types Associated with Multiple Sclerosis," J. of Experimental Medicine (Jan. 1991), 173:19-24
Wraith et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy," Cell (Oct. 1989), 59:247-255
Wraith et al., "T Cell Recognition as the Target For Immune Intervention in Autoimmune Disease," Cell (Jun. 1989), 57:709-715
Acha-Orbea et al., "Limited Heterogeneity of T Cell Receptors from lymphocytes Mediating Autoimmune Encephalomyelitis Allows Specific Immune Intervention," Cell (Jul. 1988), 54:263-27
February 26, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
